IDXX 151.93 Idexx Laboratories $IDXX Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 12, 2014 at 12:27 PM

IDXX 151.93 Idexx Laboratories $IDXX Hit a 52 week high of 152.20 Closing the day 09:43 at 151.93 -0.26 -0.17% With a day low of 151.40 and a total volume of 9,282.

IDXX Recent Posts: http://investorshangout.com/IDEXX-Laboratorie...DXX-54421/

IDXX Idexx Laboratories Recent Headline News

Uptrend Call Working As Idexx Laboratories Stock Rises 24.1% (IDXX)
Comtex SmarTrend(R) - 1 hr 30 mins ago
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on October 21st, 2014 at $122.52. In approximately 3 weeks, Idexx Laboratories has returned 24.07% as of today's recent price of $152.00.
IDXX: 152.55 (+0.36)

Trade-Ideas: Idexx Laboratories (IDXX) Is Today's Strong And Under The Radar Stock
at The Street - Tue Nov 11, 9:42AM CST
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a strong and under the radar candidate
IDXX: 152.55 (+0.36)

SmarTrend Watching for Potential Pullback in Shares of Idexx Laboratories After 1.39% Gain
Comtex SmarTrend(R) - Mon Nov 10, 5:17PM CST
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $144.18 to a high of $147.67. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $146.00 on volume of 560,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IDXX: 152.55 (+0.36)

Idexx Laboratories Earnings Hindsight: Up 7.4% in Last 17 Days (IDXX)
Comtex SmarTrend(R) - Mon Nov 10, 1:31PM CST
17 days ago, on October 24th, 2014, Idexx Laboratories (NASDAQ:IDXX) reported its earnings. Analysts, on average, expected earnings of $0.86 per share on sales of $371.3 million. Idexx Laboratories actually reported earnings of $1.05 per share on sales of $383.5 million, beating EPS estimates by $0.19 and beating revenue estimates by $12.2 million. Since the company's report, shares of Idexx Laboratories have risen from $135.20 to $145.16, representing a gain of 7.4% in the past 17 days.
IDXX: 152.55 (+0.36)

Idexx Laboratories Has Returned 17.5% Since SmarTrend Recommendation (IDXX)
Comtex SmarTrend(R) - Wed Nov 05, 9:25AM CST
SmarTrend identified an Uptrend for Idexx Laboratories (NASDAQ:IDXX) on October 21st, 2014 at $122.52. In approximately 2 weeks, Idexx Laboratories has returned 17.52% as of today's recent price of $143.98.
IDXX: 152.55 (+0.36)

Comparing America's 3 Largest Diagnostic Substances Companies
Joseph Cafariello - at Seeking Alpha - Mon Nov 03, 12:03PM CST

QDEL: 28.19 (-0.15), NEOG: 43.87 (-0.32), IDXX: 152.55 (+0.36)

Quarterly Earnings Releases and Recognitions - Research Reports on GlaxoSmithKline, IDEXX, BioMarin, GE and Lockheed Martin
PR Newswire - Wed Oct 29, 8:30AM CDT
Today, Analysts Review released its research reports regarding GlaxoSmithKline plc (NYSE: GSK), IDEXX Laboratories, Inc. (NASDAQ: IDXX), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), General Electric Company (NYSE: GE) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7542-100free.
LMT: 187.59 (+0.47), GE: 26.53 (+0.15), BMRN: 85.87 (-0.25), IDXX: 152.55 (+0.36), GSK: 45.62 (-0.34), NVS: 92.93 (+0.16)

IDEXX Laboratories (IDXX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:57AM CDT
IDEXX Laboratories (IDXX) Shares March Higher, Can It Continue?
IDXX: 152.55 (+0.36)

IDEXX Tops Q3 Earnings and Revenues; Guidance Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:10PM CDT
Since the news release, IDEXX's (IDXX) share price has climbed 9.8% to eventually close at $138.76 yesterday.
ATEC: 1.45 (+0.03), EW: 123.39 (-1.40), IDXX: 152.55 (+0.36), ANGO: 16.82 (-0.14)

Today's Strong And Under The Radar Stock Is Idexx Laboratories (IDXX)
at The Street - Tue Oct 28, 8:51AM CDT
Trade-Ideas LLC identified Idexx Laboratories (IDXX) as a strong and under the radar candidate
IDXX: 152.55 (+0.36)

IDEXX Laboratories, Inc. Is as Fit as a Butcher's Dog
Brian Orelli, The Motley Fool - Motley Fool - Fri Oct 24, 6:56PM CDT
Shares of IDEXX Laboratories jumped 7% today after reporting a solid third quarter, raising 2014 guidance, and issuing 2015 guidance that looks even better. The stock of the animal health-test provider soared to a 52-week and all-time high. ...
IDXX: 152.55 (+0.36)

Idexx Laboratories Set to Possibly Pullback After Yesterday's Rally of 7.00%
Comtex SmarTrend(R) - Fri Oct 24, 4:12PM CDT
Idexx Laboratories (NASDAQ:IDXX) traded in a range yesterday that spanned from a low of $130.06 to a high of $140.42. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $126.42 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
IDXX: 152.55 (+0.36)

IDEXX Laboratories' (IDXX) CEO Jon Ayers on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 24, 1:02PM CDT

IDXX: 152.55 (+0.36)

Idexx Q3 income up 14%
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 10:00AM CDT

IDXX: 152.55 (+0.36)

Idexx beats Street 3Q forecasts
Automated Insights - Fri Oct 24, 6:27AM CDT
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported net income of $52.1 million in its third quarter.
IDXX: 152.55 (+0.36)

IDEXX Laboratories beats by $0.15, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 6:07AM CDT

IDXX: 152.55 (+0.36)

IDEXX Laboratories Announces Third Quarter Results
PR Newswire - Fri Oct 24, 6:00AM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) today reported that revenues for the third quarter of 2014 increased 13% versus the prior year period to $384 million. Organic revenue growth1 for the third quarter of 2014 versus the prior year period was also 13%, or 11% normalized for changes in distributor inventory2. Earnings per diluted share ("EPS"

for the quarter ended September 30, 2014 increased 21% from the prior year period to $1.03. Adjusted EPS3 for the quarter was $1.05.
IDXX: 152.55 (+0.36)

Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 4:30PM CDT

WYN: 79.52 (+0.21), SFE: 19.59 (-0.17), F: 14.53 (+0.16), OCR: 68.67 (-0.34), B: 36.77 (+0.13), SXC: 22.85 (+0.05), VTR: 68.32 (-0.20), UPS: 108.52 (-0.24), DLPH: 70.18 (-0.06), CHH: 53.19 (-0.06), LYB: 87.09 (-1.45), COG: 33.54 (-0.05), SHPG: 200.29 (-1.92), TCB: 15.95 (+0.24), AVY: 47.93 (-0.03), AAN: 27.26 (+0.17), MGLN: 61.51 (+0.12), STT: 77.10 (-0.58), FNFG: 7.78 (+0.27), IMGN: 9.79 (-0.31), EDU: 21.88 (+0.04), BMY: 58.76 (+0.04), DTE: 81.06 (-1.73), LEA: 91.69 (-0.93), MCO: 99.78 (+0.47), FLIR: 33.19 (+0.20), IMS: 24.61 (+0.19), LPNT: 64.57 (-1.37), ERIC: 11.77 (-0.15), PG: 89.69 (+0.02), IDXX: 152.55 (+0.36), WBC: 101.82 (-0.03), NDAQ: 44.15 (-0.12), CL: 68.62 (+0.15)

Oracle Enterprise Manager Enables Seamless IT Management and Visibility for IDEXX Laboratories
Marketwired - Wed Oct 15, 7:04AM CDT
Oracle (NYSE: ORCL)
IDXX: 152.55 (+0.36), ORCL: 40.47 (unch)

IDEXX Laboratories to Release 2014 Third Quarter Financial Results
PR Newswire - Tue Oct 14, 12:45PM CDT
IDEXX Laboratories, Inc. (NASDAQ: IDXX) has scheduled the release of its 2014 third quarter financial results for Friday, October 24, 2014 at approximately 7:00 a.m. ET. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
IDXX: 152.55 (+0.36)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TilePix Expands into Walmart with Nail-Free Decor Launch

TilePix Makes Big Moves with Walmart TilePix is launching their new line of nail-free wall décor at Walmart—this ain’t your grandma’s wall art. This company's bringing their magnetic, nail-free wizardry to retail stores nationwide for the first time, and they’ve chosen a real heavyweight partner—Walmart. What comes in the package? Well, they’re dealing in...

2GenPen & LordCap Team Up: Game-Changer in ABS?

New Kids on the Structured Credit Block? Well, it looks like we're in for a ride with 2GenPen teaming up with Lord Capital to shake up the asset-backed securities (ABS) world. They're strutting their stuff by launching a strategic collaboration to boost credit analysis. Think of it as a power-up for ABS transactions—because nobody loves a murky credit rating. The Heart...

Costa Rican Firms Chase Growth at SIAL Paris 2026

Chasing Growth in Paris: Costa Rica's Bold Move When it comes to playing the global field, Costa Rica isn't just sitting back; they're on the move. Picture this: PROCOMER, along with 18 standout companies, landed smack dab in the grand hustle and bustle of SIAL Paris 2026. This isn't some leisurely stroll—it's a calculated sprint toward expanding their reach across...

Florida Cancer Center Expands Expertise with New Oncologist

Welcoming a Highly Skilled Oncologist to Fort Myers There's an old saying in the world of investing: follow the expertise. And when it comes to healthcare, especially cancer treatment, expertise can make a world of difference. Florida Cancer Specialists & Research Institute (FCS) is throwing its hat in the ring with authority, as they welcome Dr. Kelly Elleson, a surgical...

Kansai Medical Ushers in New Era of Cancer Research

Breaking Ground in Cancer Treatment Trials I've seen some thrilling breakthroughs in my time following the pharmaceutical industry, but what Kansai Medical University and Daiichi Sankyo are doing elevates the game. They're rolling out the first patient dose of DS1025 in Osaka, Japan—a move that marks the onset of a global Phase 1 clinical trial. This is no ordinary...

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Chicago Scenic Studios’ Equipment Up for Grabs in Auction

A Peek into the Sale: What's on the Block? Get that coffee brewing and settle in, because we've got to unpack some interesting stuff happening with Chicago Scenic Studios. This isn't just any Craigslist decampment—Integra Asset Solutions is rolling out an online auction come October 27 that’ll have equipment-savvy investors’ ears perking up like they just snagged a...

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

AEVEX Facing Class Action: Deadline Looms for Investors

The Clock is Ticking for AVEX Investors News flash, folks: If you bought into AEVEX Corp. (NYSE: AVEX) between mid-April and early June this year, you might have a legal gold mine on your hands—or at least a shot to join a class action that could knock some dollars back into your pocket. Mark it on your calendar—October 20, 2026, is the last call to toss your hat in...

Solvang Teamsters Triumph in Labor Standoff

Solvang Strikers Prevail with New Deal Staring down the barrel of a five-week standoff, the hard-nosed workers of Solvang just proved exactly what grit can get you. The City of Solvang and the steadfast members of Teamsters Local 986 wrapped up their punchy back-and-forth by clinching a contract that ups the ante on wages and job respect. For a bunch who stuck it out on...